DeCode’s Genetic Breakthrough Barely Registers DeCode Genetics published an important genetic map–assembled by methods very different from those used to create the sequence of the human genome–that will make it much easier for scientists to hunt down new genes linked to disease. But DeCode’s stock continues to languish.
Celera abandons gene sequencing The company that shared the glory for unravelling the code of life of human beings has turned its back on gene sequencing. Celera Genomics of Rockville, Maryland, announced this week that it is to develop drugs instead
Biotrends Two major reports highlight the globalization of biotechnology and the battle within the U.S. for regional supremacy
Where the Biotech Bets Are John McCamant of The Medical Technology Stock Letter tells where he’s making his in this poorly performing sector.
Biotech lobbyists’ clout grows in Washington The Biotechnology Industry Organization is still unpacking from its move into a bigger office a few blocks from the White House, underscoring the outfit’s rapid climb to lobbying juggernaut status.
Gene Doping Threatens to Transform Sports “If it does take off, sport as we know it will disappear”
FDA Acts To Speed Bioterror Medicines Responding to the threat of anthrax and other forms of chemical and biological terrorism, the Food and Drug Administration adopted new rules yesterday that will speed the approval of drugs that could protect people from attacks.
A Challenge to Science and Nature A new journal will challenge publishing behemoths such as Science, Nature and Cell by offering free access to research articles immediately upon publication on the Web.
Life after Venter At Celera Genomics, a new president and questions about the company’s direction.
Biotech heads west for VC The pot of gold to fund biotech research in Memphis may come from Little Rock